Rifaximin for Preventing Progression and Complications in Patients With Decompensated Liver Cirrhosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-18

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

It is still not clear whether rifaximin can prevent the progression of liver cirrhosis, reduce the overall complications and improve the survival in patients with decompensated cirrhosis. This is a multi-center open-labelled randomized prospective study to evaluate the efficacy and safety of rifaximin in preventing the progression and complications in cirrhotic patients, and explore its reasonable dosage and possible mechanism. A total of 150 patients with decompensated liver cirrhosis will be enrolled in the study and randomly divided into three groups (the control group (A), the low-dose rifaximin treatment group (B), and conventional dose rifaximin treatment group (C)) with a ratio of 1:2:2. The patients in group B are given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks, and the patients in group C are delivered 1200mg/d (600mg, bid) of rifaximin .During the entire study period, all other therapeutic strategies are kept unchanged in all the groups as long as possible. The proportion of patients with progression of cirrhosis, the incidence of total complications and each complication, survival rate and time, liver function and adverse events will be compared among the three groups. This study might provide a new feasible method with clinical application prospects for preventing the progression and reducing the incidence of liver cirrhosis related complications, improve the prognosis of patients with decompensated liver cirrhosis, and save medical resources.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Rifaximin on Portal Vein Thrombosis

NCT03631147

Cirrhosis Portal Vein Thrombosis

UNKNOWN NA

Rifaximin Prophylaxis for Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome in Cirrhotic Patients

NCT05621005

Ascites Infection

COMPLETED PHASE2

Efficacy and Safety of Rifaximin in Treating MAFLD

NCT07185932

Metabolic-associated Fatty Liver Disease

RECRUITING EARLY_PHASE1

Rifaximin in Fatty Liver Disease

NCT01355575

Nonalcoholic Fatty Liver Disease NAFLD Nonalcoholic Steatohepatitis

TERMINATED PHASE4

Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT02884037

Non-alcoholic Fatty Liver Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rifaximin has been recommended as a prophylactic drug for hepatic encephalopathy (HE) and spontaneous bacterial peritonitis (SBP), the two major complications of liver cirrhosis. However, it is still not clear whether rifaximin can prevent the progression of liver cirrhosis, reduce the overall complications and improve the survival in patients with decompensated cirrhosis. Additionally, the role of rifaximin in the treatment of liver cirrhosis has not been fully clarified. We designed a multi-center open-labelled randomized prospective study to evaluate the efficacy and safety of rifaximin in preventing the progression and complications in cirrhotic patients, and explore its reasonable dosage and possible mechanism. A total of 150 patients with decompensated liver cirrhosis will be enrolled in the study. They will be randomly divided into three groups (the control group (A), the low-dose rifaximin treatment group (B), and conventional dose rifaximin treatment group (C)) with a ratio of 1:2:2. The patients in group B are given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks, and the patients in group C are delivered 1200mg/d (600mg, bid) of rifaximin .During the entire study period, all other therapeutic strategies, such as antiviral agents, non-selective beta-blockers, liver protectants, and diuretics, are kept unchanged in all the groups as long as possible. The proportion of patients with progression of cirrhosis, acute decompensation, acute-on-chronic liver failure (ACLF), decompensation and stable decompensated cirrhosis, the incidence of total complications and each complication, survival rate and time, liver function and adverse events will be compared among the three groups. This study might provide a new feasible method with clinical application prospects for preventing the progression and reducing the incidence of liver cirrhosis related complications, improve the prognosis of patients with decompensated liver cirrhosis, and save medical resources.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Decompensated Cirrhosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control group

Group A: Patients in the control group were administered only conventional therapy

Group Type NO_INTERVENTION

No interventions assigned to this group

the low-dose rifaximin treatment group

Group B

Group Type EXPERIMENTAL

Low-dose of Rifaximin

Intervention Type DRUG

The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks

the conventional dose rifaximin treatment group

Group C

Group Type EXPERIMENTAL

Conventional dose of Rifaximin

Intervention Type DRUG

the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Low-dose of Rifaximin

The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks

Intervention Type DRUG

Conventional dose of Rifaximin

the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Low-dose of Xifaxan Conventional dose of Xifaxan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* With a clinical diagnosis of decompensated liver cirrhosis on the basis of typical clinical manifestations, laboratory tests, imaging appearances and/or representative pathology results of liver biopsy. Decompensation of the disease was defined by at least having an episode of severe complications, including ascites, SBP, EGVB and HE.

Exclusion Criteria

* Episodes of overt HE, EGVB or SBP within 4 weeks before the screening visit
* Uncontrolled severe infection or antibiotic use within 2 weeks before the screening visit
* Hepatitis B virus (HBV) DNA ≥ 500 copy/mL，or receipt of standard antiviral treatment for hepatitis B for less than 12 months
* Receiving antiviral treatment for hepatitis C or receipt of antiviral treatment for hepatitis C within 12 months before the screening visit
* If patients with autoimmune liver disease have been treated with ursodeoxycholic acid, hormone or other immunosuppressants, the dose stability time is less than 6 months
* With history of alcoholism in the last 12 weeks or unwilling to stop alcohol abuse after inclusion (≥ 20 g/day for women or ≥ 30 g/day for men)
* With confirmed or suspected malignancies
* Severe jaundice (serum total bilirubin level ≥ 85 μmol/L)
* Obvious renal dysfunction (serum creatinine ≥ 1.2-fold of upper normal limits)
* Severe electrolyte abnormality (serum sodium level \< 125 mmol/L )
* Life-threatening leucocytopenia (white blood cell count \< 1 × 10\^9/L )
* Poorly controlled hypertension, diabetes mellitus or other severe heart and respiratory diseases (NYHA Ⅲ/Ⅳ, COPD GOLD C)
* With drug abuse, methadone treatment, drug dependence or mental illness
* HIV seropositivity
* Known to be allergic to rifaximin
* Pregnant and lactating women or women who do not rule out pregnancy
* Those who have participated in other drug trials within 12 weeks

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No